

Expanded Genomic Marker Testing for Somatic Tumours

To our valued clients:

Beginning August 2019, the Molecular Diagnostic Laboratory at KHSC is pleased to announce the implementation of a new massively parallel sequencing panel based assay for investigation of genomic markers in solid tumours. The OncoPrint Comprehensive v3 (OCAv3) assay interrogates the coding sequence of >130 oncogenes and tumour suppressors, simultaneously getting information about key copy number changes and fusion transcripts. This assay replaces the HotSpot v2 assay which interrogated the coding regions of 50 genes.

For all clinical specimens, we will continue to report only the relevant biomarkers currently funded by the MOHLTC. As new markers are funded, we will validate and report data for additional genes, as appropriate.

For research studies, including OCTANE and PERFCT, information from the entire panel can be made available. For OCTANE, patient consent allows the reporting of all clinically variants identified as a research report and these will continue to be sent directly to referring oncologists. For PERFCT, the full dataset will be captured and stored in the PERFCT database, and can be available to researchers following approval from the PERFCT steering committee.

Please direct questions about the assay to Dr. Harriet Feilotter at hf4@queensu.ca or at 613 533 2932.

Sincerely,



Harriet Feilotter, PhD, FCCMG, FACMG

Professor, Department of Pathology and Molecular Medicine, Queen's University

Director, Molecular Diagnostics Laboratory, Kingston Health Sciences Centre